China wants commercial insurance firms to invest in the development of homegrown medicines, Beijing’s latest bid to support its burgeoning biotech and pharmaceutical sector.
Commercial insurers have been encouraged to set up investment funds to provide long-term financing and “patience capital” to nurture the creation of innovative drugs, according to a document released Tuesday by China’s National Health Security Administration, which overseas its state medical insurance fund.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.